Dobson R.,G. Giovannoni. R. . .Multiple sclerosis - A review. European Journal of Neurology, 26(2019) : 27-40.
Noto S.,Miyake S. .2020 .Gut dysbiosis and multiple sclerosis. ” Clinical Immunology, 235 : .
Brownlee W.J. .2017 .Diagnosis of multiple sclerosis: Progress and challenges. The Lancet, 6736(16) : 30959-1346.
Ford H. “ . .Clinical presentation and diagnosis of multiple sclerosis. ” Clinical Medicine, 20(2020) : 0292-383.
Ruck T. . .Alemtuzumab in multiple sclerosis: Mechanism of action and beyond. International Journal of Molecular Sciences, 16(2015) : 16414-16439.
Costelloe L. . .Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis. ” Expert Review of Neurotherapeutics, 12(2012) : 335-341.
Ruck T. . .Alemtuzumab-induced immune phenotype and repertoire changes: Implications for secondary autoimmunity. ” Brain, 145(2022) : 1711-1725.
Scappaticcio L. . .Alemtuzumab-induced thyroid events in multiple sclerosis: A systematic review and meta-analysis. ” Journal of Endocrinological Investigation, 43(2020) : 219-229.
Yang J. .2024 .Risk of secondary autoimmune diseases with alemtuzumab treatment for multiple sclerosis: A systematic review and meta-analysis. ” Frontiers in Immunology, 15 : .
Moher D. .2010 .Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. International Journal of Surgery, 02(2010) : 336-341.
Carroll . .“2017 McDonald MS diagnostic criteria: Evidencebased revisions. ” Multiple Sclerosis Journal, 24(2018) : 92-95.
Wells G.A. .2000 .The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomized Studies in MetaAnalyses. , : .
Higgins J.P.T. .2011 .The Cochrane Collaboration's tool for assessing risk of bias in randomized trials. ” BMJ, 343 : .
Milo R.,Alemtuzumab R. . .. , : .
Havrdova E. . .Alemtuzumab in the treatment of multiple sclerosis: Key clinical trial results and considerations for use. ” Therapeutic Advances in Neurological Disorders, 8(2015) : 31-45.
Daniels G.H. . .Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsingremitting multiple sclerosis. The Journal of Clinical Endocrinology and Metabolism, 99(2014) : 2201-89.
Manso J. . .Alemtuzumab-induced autoimmune thyroid events in patients with relapsing-remitting multiple sclerosis. ” Clinical Endocrinology, 97(2022) : 331-338.
Dayan C.M. .2023 .Endocrine and multiple sclerosis outcomes in patients with autoimmune thyroid events in the alemtuzumab CARE-MS studies. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 9(1) : .
Decallonne B. . .Thyroid disorders in alemtuzumabtreated multiple sclerosis patients. ” Acta Neurologica Belgica, 118(2018) : 153-159.
Conway J.V. .2022 .Graves' disease following commencement of alemtuzumab therapy. ” Journal of Clinical and Translational Endocrinology: Case Reports, 25 : .
Carrion Santiago,A.M. Santiago,Agosto-Vargas. Y. . .An unusual etiology of Graves' disease:. Alemtuzumab.” Journal of the Endocrine Society, 5(2021) : A921-A922.
Pariani N. . .Alemtuzumab-induced thyroid dysfunction exhibits distinctive clinical and immunological features. The Journal of Clinical Endocrinology and Metabolism, 103(2018) : 00359-3018.
Rapier B. .2020 .Progression of Graves' disease to Hashimoto's thyroiditis following alemtuzumab therapy. ” Journal of the Endocrine Society, 518(suppl) : .
Gong M.S. .1962 .Graves' disease secondary to alemtuzumab use. ” Journal of the Endocrine Society, 7(suppl) : .
Rodríguez de Castro B. . .Alemtuzumab for relapsing multiple sclerosis in clinical practice. International Journal of Risk and Safety in Medicine, 31(2020) : 259-265.
Willis M. . .Alemtuzumab for multiple sclerosis: Longterm follow-up in a multi-centre cohort. ” Multiple Sclerosis Journal, 22(2016) : 1215-1223.
Bose G. .2021 .A real-world single-centre analysis of alemtuzumab and cladribine for multiple sclerosis. ” Multiple Sclerosis and Related Disorders, 52 : .
Sovetkina A. . .Development of autoimmune thyroid disease in multiple sclerosis patient's post-alemtuzumab. The Journal of Clinical Endocrinology and Metabolism, 105(2020) : e3392-e3399.
Yap S.M. .2020 .Alemtuzumab-related thyroid disease in people with multiple sclerosis. ” Multiple Sclerosis Journal - Experimental, Translational and Clinical, 6(2) : .
Coles A.J. .1999 .Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis.” The Lancet. , 354(9191) : 1691-1695.
Eichau S. .2023 .Results of treatment with alemtuzumab in a Spanish cohort. , 14 : .
Fox E. .2011 .A single-arm, open-label study of alemtuzumab. European Journal of Neurology, 03507(2012) : 1331-311.
Rotondi M. .2017 .Autoimmune thyroid diseases in patients treated with alemtuzumab. ” Frontiers in Endocrinology, 8 : .
Kazakou P. . .Thyroid autoimmunity following alemtuzumab treatment. ” Clinical and Experimental Medicine, 23(2023) : 2885-2894.
Hansen J.F. .2024 .Alemtuzumab-induced thyroid disease. ” Multiple Sclerosis and Related Disorders, 91 : .
Ragavan S. .2022 .Alemtuzumab-induced autoimmune thyroid dysfunction. ” Cureus, 14(3) : .
Sandgren S. .2023 .The role of autoimmune antibodies to predict secondary autoimmunity. , 14 : .
Muller I. .2018 .Longitudinal characterization of autoantibodies to the thyrotropin receptor. ” Thyroid, 28(12) : 1682-1693.
Tran B. .2024 .. Fluctuating Graves' disease.” Journal of the Endocrine Society, 8(suppl) : 1960.